39.05
Schlusskurs vom Vortag:
$38.05
Offen:
$38.16
24-Stunden-Volumen:
1.40M
Relative Volume:
0.71
Marktkapitalisierung:
$3.38B
Einnahmen:
$170.10M
Nettoeinkommen (Verlust:
$-239.59M
KGV:
-13.95
EPS:
-2.8
Netto-Cashflow:
$-191.20M
1W Leistung:
+6.55%
1M Leistung:
+4.17%
6M Leistung:
-20.84%
1J Leistung:
-34.38%
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Vergleichen Sie CRSP mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CRSP
Crispr Therapeutics Ag
|
39.17 | 3.21B | 170.10M | -239.59M | -191.20M | -2.80 |
![]()
ONC
Beone Medicines Ltd Adr
|
258.65 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
446.97 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.2807 | 41.83M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
86.13 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
485.64 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
2024-08-06 | Bestätigt | Needham | Buy |
2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2023-09-27 | Eingeleitet | Mizuho | Buy |
2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
2023-05-30 | Eingeleitet | William Blair | Outperform |
2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
2021-12-07 | Eingeleitet | Cowen | Market Perform |
2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
2020-12-10 | Bestätigt | Needham | Buy |
2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2020-10-05 | Eingeleitet | BofA Securities | Buy |
2020-07-28 | Bestätigt | Needham | Buy |
2020-07-14 | Eingeleitet | SunTrust | Buy |
2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
2020-03-05 | Eingeleitet | Stifel | Hold |
2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
2019-08-01 | Eingeleitet | Jefferies | Buy |
2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
2019-06-10 | Eingeleitet | ROTH Capital | Buy |
2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue? - Yahoo
CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Raised by Green Alpha Advisors LLC - MarketBeat
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - Yahoo Finance
Promising Growth and Diversification Drive Buy Rating for Crispr Therapeutics AG - TipRanks
Can CRISPR Build On Casgevy's Success With Its In Vivo Pipeline? - Barchart.com
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Voloridge Investment Management LLC - MarketBeat
The Best Stocks to Invest $1,000 in Right Now - The Motley Fool
Capital Market Strategies LLC Buys 9,652 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Q2 EPS Forecast for CRISPR Therapeutics Increased by Analyst - MarketBeat
Insider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) Insider Sells 3,932 Shares of Stock - MarketBeat
Cas9 Technology Market Projected to Hit $30.4 Billion at a 19.81% CAGR by 2032 - industrytoday.co.uk
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip - Yahoo Finance
Trading (CRSP) With Integrated Risk Controls - news.stocktradersdaily.com
Top 5 CRISPR Companies To Invest In (June 2025) - Securities.io
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Zacks Research Has Positive Outlook for CRSP Q2 Earnings - Defense World
Two Sigma Advisers LP Buys 28,400 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $71.75 Consensus Target Price from Analysts - MarketBeat
ARK Investment Expands Stake in Crispr Therapeutics (CRSP) | CRS - GuruFocus
ARK Investment Expands Stake in Crispr Therapeutics (CRSP) | CRSP Stock News - GuruFocus
Cathie Wood’s ARK Investment buys 294K shares of Crispr Therapeutics today - TipRanks
ARK Investment Increases Stake in Crispr Therapeutics (CRSP) | CRSP Stock News - GuruFocus
CRISPR Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Two Sigma Investments LP Grows Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr Therapeutics, Clover Health among healthcare stocks to join Russell 3000; INO, SAVA to exit - Seeking Alpha
CRISPR and Cas Genes Market Set to Witness Significant Growth - openPR.com
Cathie Wood’s ARK Investment buys 262K shares of Crispr Therapeutics today - TipRanks
Ameriprise Financial Inc. Acquires 18,412 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Westwood Holdings Group Inc. Raises Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - MSN
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics' (CRSP) "Market Outperform" Rating Reiterated at JMP Securities - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Earns "Buy" Rating from HC Wainwright - MarketBeat
CRISPR Therapeutics’ SWOT analysis: gene-editing pioneer’s stock faces pivotal year - Investing.com Nigeria
Q2 EPS Estimate for CRISPR Therapeutics Decreased by Analyst - MarketBeat
Rafferty Asset Management LLC Lowers Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Northern Trust Corp Has $10.12 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Cetera Investment Advisers Reduces Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
Q2 EPS Estimate for CRISPR Therapeutics Lowered by Analyst - Defense World
Transcript : CRISPR Therapeutics AG Presents at H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025, May-20-2025 04 - marketscreener.com
Transcript : CRISPR Therapeutics AG Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 10 - marketscreener.com
CRSP July 3rd Options Begin Trading - Nasdaq
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):